Get Your Personalized Supplement StackSupplement Stack Quiz

Ancient Peat and Apple Extract

Q: Is it safe?

Yes, based on current evidence from a 12-week trial, no adverse effects or negative changes in blood markers were reported at the recommended dose.

Q: How soon will I see results?

Improvements in strength and power were observed after 12 weeks of consistent supplementation combined with a resistance training program.

Q: Can it replace creatine?

No direct comparison studies exist. Creatine has a more robust and extensive evidence base for strength and performance enhancement.

Q: Is it effective without training?

No, the benefits observed in studies were in conjunction with a structured resistance training program. It is not effective without concurrent exercise.

Q: Is it suitable for women?

Currently, there is no specific data available on the safety or efficacy of ElevATP in women. Research has been limited to male participants.

Also known as: ancient peat extract and apple extract blend, ancient peat extract, apple extract, ElevATP

Overview

ElevATP is a proprietary blend primarily composed of ancient peat extract and apple extract, marketed as an ergogenic aid. Ancient peat is a naturally occurring organic material rich in humic substances and minerals, formed from decomposed plant matter over millennia. Apple extract is derived from apples and contains various polyphenols and bioactive compounds. This blend is designed to enhance cellular ATP (adenosine triphosphate) production, the primary energy currency of cells, thereby potentially improving athletic performance, muscle strength, and power output during resistance training. It is claimed to increase mitochondrial ATP synthesis, leading to improved muscle function and recovery. While research is in its early stages, a randomized controlled trial has shown promising results in enhancing strength and power in resistance-trained males.

Benefits

ElevATP has demonstrated significant benefits in enhancing athletic performance, particularly in strength and power. A 2016 randomized controlled trial involving 25 resistance-trained males showed that daily supplementation with 150 mg of ElevATP over 12 weeks, combined with periodized resistance training, led to statistically significant increases in squat 1-repetition maximum (1RM), deadlift 1RM, and vertical jump peak power and peak velocity. These improvements were notably greater than those observed in the placebo group (p < 0.05), indicating enhanced strength and explosive power adaptations. While trends toward improved Wingate peak power and power-to-mass ratio were observed, they did not reach statistical significance. The evidence is currently limited to healthy, resistance-trained young males, and the effects were observed over a 12-week supplementation period, suggesting that benefits accrue over time with consistent use and concurrent training.

How it works

ElevATP primarily functions by stimulating mitochondrial ATP production, thereby increasing the cellular energy available for various physiological processes, especially within skeletal muscle cells. While the exact molecular targets are not fully elucidated, the blend is believed to interact with mitochondrial enzymes and pathways involved in oxidative phosphorylation, the main process by which cells generate ATP. By enhancing ATP synthesis, ElevATP aims to improve energy metabolism during high-intensity exercise, allowing for greater muscle contraction force, power output, and potentially faster recovery. The proprietary blend is orally bioavailable, enabling its components to be absorbed and exert their effects within the body's energy systems.

Side effects

Based on current research, ElevATP appears to have a favorable safety profile at the tested dose. A 12-week randomized controlled trial reported no adverse effects or significant changes in hematological parameters (blood markers) in resistance-trained males supplementing with 150 mg daily. No common (greater than 5%), uncommon (1-5%), or rare (less than 1%) side effects have been reported in the available studies. There are no documented drug interactions, though data in this area are limited. Contraindications have not been established due to the limited scope of research. It is important to note that safety and efficacy have not been studied in women, older adults, or individuals with pre-existing medical conditions, so caution is advised for these populations until further research is conducted. Long-term safety data beyond 12 weeks are also not available.

Dosage

The minimum effective dose identified from the primary research is 150 mg daily of the proprietary ElevATP blend. This dosage was used in the randomized controlled trial where significant improvements in strength and power were observed. Currently, this is the only dose that has been rigorously studied, so optimal and maximum safe dosage ranges are not yet established. ElevATP is typically taken once daily, though the specific timing relative to exercise has not been specified as critical for its effects. It is available in oral capsule or powder form. No specific cofactors are reported to be required for its absorption or efficacy. Users should adhere to the recommended 150 mg daily dose, as higher doses have not been tested for safety or increased efficacy.

FAQs

Is it safe?

Yes, based on current evidence from a 12-week trial, no adverse effects or negative changes in blood markers were reported at the recommended dose.

How soon will I see results?

Improvements in strength and power were observed after 12 weeks of consistent supplementation combined with a resistance training program.

Can it replace creatine?

No direct comparison studies exist. Creatine has a more robust and extensive evidence base for strength and performance enhancement.

Is it effective without training?

No, the benefits observed in studies were in conjunction with a structured resistance training program. It is not effective without concurrent exercise.

Is it suitable for women?

Currently, there is no specific data available on the safety or efficacy of ElevATP in women. Research has been limited to male participants.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC4950767/ – This randomized, double-blind, placebo-controlled trial investigated the effects of 150 mg/day ElevATP on strength and power in 25 resistance-trained males over 12 weeks. Results showed significant increases in squat and deadlift 1RM, and vertical jump power and velocity in the ElevATP group compared to placebo, indicating its ergogenic potential. No adverse effects were reported.
https://resolve.cambridge.org/core/services/aop-cambridge-core/download/cited-by?doi=10.1017%2FS0007114510003570&productType=JOURNAL_ARTICLE&productId=E3A73C525E351A558D7D81D1AE9459A1 – This source, cited as a safety assessment within the same trial framework, confirmed no negative impact on hematological parameters in the participants. It supports the short-term safety of ElevATP at the tested dose, showing no adverse changes in blood markers over the 12-week study period.